Ocular Therapeutix (NASDAQ:OCUL) Stock Gets Price Target Bump from HC Wainwright

Key Points

• HC Wainwright raised its price target on Ocular Therapeutix from $25 to $28 and maintained a Buy rating; the target implied 308.76% upside from the stock’s then-current price. Analysts’ consensus rating was Moderate Buy, with an average target of $23.83.
• The company’s latest quarter fell short of expectations: it reported a $0.42-per-share loss versus the expected $0.36 loss, and revenue of $12.87 million versus $14.27 million expected, down 11.5% year over year.
• Ocular plans to submit an NDA for AXPAXLI in Q4 2026, and its reported $530.6 million cash balance is expected to fund operations into 2028, easing near-term financing concerns.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) had its target price upped by analysts at HC Wainwright from $25.00 to $28.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price target indicates a potential upside of 308.76% from the stock's current price.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Ocular Therapeutix from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ocular Therapeutix in a research report on Thursday, October 15th. Needham & Company LLC reiterated a "buy" rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research note on Monday, October 19th. UBS Group assumed coverage on shares of Ocular Therapeutix in a report on Sunday, October 11th. They issued a "buy" rating and a $14.00 price objective for the company. Finally, Chardan Capital restated a "buy" rating and set a $23.00 target price on shares of Ocular Therapeutix in a research report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Ocular Therapeutix has a consensus rating of "Moderate Buy" and an average price target of $23.83.

Ocular Therapeutix Price Performance

Shares of OCUL stock opened at $6.85 on Tuesday. The firm has a 50 day moving average price of $8.33 and a two-hundred day moving average price of $9.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. Ocular Therapeutix has a 12-month low of $6.00 and a 12-month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.06). The firm had revenue of $12.87 million for the quarter, compared to the consensus estimate of $14.27 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. Ocular Therapeutix's revenue for the quarter was down 11.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.38) EPS. Research analysts predict that Ocular Therapeutix will post -1.47 earnings per share for the current year.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Todd Anderman sold 11,984 shares of the company's stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $7.29, for a total transaction of $87,363.36. Following the completion of the sale, the insider directly owned 140,484 shares in the company, valued at $1,024,128.36. This represents a 7.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 9,990 shares of the firm's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $7.05, for a total value of $70,429.50. Following the completion of the sale, the insider directly owned 254,388 shares in the company, valued at $1,793,435.40. This trade represents a 3.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 98,090 shares of company stock worth $787,920 over the last quarter. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ocular Therapeutix

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Ocular Therapeutix in the 2nd quarter valued at approximately $190,278,000. Octagon Capital Advisors LP grew its stake in shares of Ocular Therapeutix by 20.7% during the first quarter. Octagon Capital Advisors LP now owns 3,166,600 shares of the biopharmaceutical company's stock worth $26,821,000 after buying an additional 543,000 shares during the last quarter. Commodore Capital LP bought a new stake in shares of Ocular Therapeutix during the first quarter worth $21,810,000. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 6.0% during the 3rd quarter. Deltec Asset Management LLC now owns 2,623,597 shares of the biopharmaceutical company's stock valued at $20,123,000 after acquiring an additional 147,400 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Ocular Therapeutix by 44.4% during the 2nd quarter. Squarepoint Ops LLC now owns 1,415,913 shares of the biopharmaceutical company's stock valued at $13,904,000 after acquiring an additional 435,156 shares in the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Ocular Therapeutix plans to submit an NDA for AXPAXLI in the fourth quarter of 2026. Its $530.6 million cash balance is expected to fund operations into 2028, reducing near-term financing concerns. Article: AXPAXLI filing plan and cash runway
• Neutral Sentiment: Insider Namrata Saroj sold 35,370 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated reason makes the transaction less indicative of a discretionary view on OCUL. SEC insider transaction filing
• Neutral Sentiment: The company appointed Riad Sherif to its board of directors, a governance change with no immediate, clear financial impact. Article: Board appointment
• Negative Sentiment: Third-quarter results missed expectations: the company reported a $0.42-per-share loss versus the expected $0.36 loss, while revenue of $12.87 million fell short of the $14.27 million consensus and declined 11.5% year over year. Article: Third-quarter earnings miss
• Negative Sentiment: Reports also pointed to costs of advancing AXPAXLI and declining DEXTENZA sales, highlighting pressure on near-term operating performance. Article: Pipeline costs and DEXTENZA sales

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.

Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

The company was founded in 2006 and serves the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.